I hope the extension trial results can renew some interest but...

I hope the extension trial results can renew some interest but the one positive to come out of the original 12 month trial - hippocampal volume - may not have been all that great according to the following opinion:

• Bruno Pietro Imbimbo
  Chiesi Farmaceutici S.p.A.

2.4.14 I do not see as particularly encouraging the trend favoring PBT2 in the rate of hippocampus atrophy compared to placebo (-2.6 percent vs. -4.0 percent), because the mean atrophy rate observed in the placebo group is in the upper range of what one would expect in mild AD subjects (Kaye et al., 2005). Thus, the apparent difference in favor of PBT2 could be by chance due to limited sample size. In addition, the positive trend observed in the hippocampal atrophy rate seems not confirmed for ventricles or cortex.